Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
Globe Newswire (Tue, 3-Mar 8:00 AM ET)
Market Chameleon (Fri, 27-Feb 2:32 AM ET)
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Thu, 26-Feb 4:05 PM ET)
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
Globe Newswire (Thu, 26-Feb 4:01 PM ET)
Globe Newswire (Thu, 26-Feb 4:01 PM ET)
Globe Newswire (Thu, 12-Feb 6:00 PM ET)
Globe Newswire (Thu, 12-Feb 9:02 AM ET)
Globe Newswire (Wed, 14-Jan 8:00 AM ET)
Globe Newswire (Mon, 12-Jan 7:30 AM ET)
Globe Newswire (Thu, 8-Jan 4:30 PM ET)
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Emergent Biosolutions trades on the NYSE stock market under the symbol EBS.
As of March 19, 2026, EBS stock price climbed to $8.08 with 657,274 million shares trading.
EBS has a beta of 1.87, meaning it tends to be more sensitive to market movements. EBS has a correlation of 0.15 to the broad based SPY ETF.
EBS has a market cap of $424.36 million. This is considered a Small Cap stock.
Last quarter Emergent Biosolutions reported $149 million in Revenue and -$.43 earnings per share. This fell short of revenue expectation by $-68 million and missed earnings estimates by -$.75.
In the last 3 years, EBS traded as high as $15.10 and as low as $1.42.
The top ETF exchange traded funds that EBS belongs to (by Net Assets): AVUV, VTI, XBI, IWM, FNDA.
EBS has outperformed the market in the last year with a return of +42.0%, while the SPY ETF gained +18.9%. However, in the most recent history, EBS shares have underperformed the stock market with its stock returning -34.3% in the last 3 month period and -7.9% for the last 2 week period, while SPY has returned -1.9% and -3.7%, respectively.
EBS support price is $7.70 and resistance is $8.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EBS shares will trade within this expected range on the day.